The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

They say that change takes time. Well, that's not the case for RNA. The small biological molecule acts like a switchboard ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

The global RNA based therapeutic market size is calculated at USD 9.46 billion in 2025 and is expected to reach around USD 40 ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

New research suggests that the formation of stress granules, clumps of proteins and RNA under stress, is a potential root ...

There are many molecules with therapeutic potential, but it can be a challenge to deliver them to the right places at the ...

Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

They say that change takes time. Well, that's not the case for RNA.The small biological molecule acts like a switchboard ...

A new model of Alzheimer's disease has been proposed, which could speed up efforts to understand and cure the complex ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...